Longevity network
Longevity Centers of America (Netzwerk)
- Hormone therapy (HRT / BHRT)
- Peptide therapy
ListedView profile →
§ — Substance profile
C
BPC-157
Body Protection Compound 157 · Pentadecapeptide BPC 157 · Synthetic gastric-derived pentadecapeptide
01 — Regulatory status
Regulatory status · United States · as of September 2026
Not FDA-approved for any use. Placed in 503A Category 2 in 2023 over immunogenicity and impurity concerns; removed from Category 2 on April 15, 2026 after nomination withdrawal — which is not a listing in Category 1. Reviewed by the Pharmacy Compounding Advisory Committee on July 23, 2026; FDA proposed not to add it to the 503A Bulks List. Compounding remains outside the 503A exemption until rulemaking concludes.
Source: FDA 503A Bulks List · PCAC meeting records · verified September 2026
- Approved drug with randomized controlled trials for the approved indication
- Human clinical data exists, but no approval for the researched use
- Animal or in-vitro data only, no controlled human trials
- No published clinical data; use rests on anecdote
A
B
C
D
Reviewed September 2026 · Sources: FDA, EMA
02 — Researched for
What is being studied.
Tendon, ligament and muscle healing; gastrointestinal mucosal protection; ulcerative colitis (the indication FDA reviewed in 2026).
03 — What the evidence shows
The published record.
Extensive rodent data on tendon-to-bone healing and mucosal protection. Human data is limited to small, short trials FDA reviewers described as underpowered; no randomized controlled trial supports the injury-recovery use that dominates marketing.
04 — What is claimed but not shown
Claimed, not demonstrated.
Accelerated recovery from sports injuries in humans; systemic anti-inflammatory benefit; safety of long-term use.
05 — Known risks
Documented risks.
Immunogenicity and impurity concerns cited by FDA; unregulated sourcing means unknown purity and dose; no long-term human safety data.
06 — Researched for these goals
Where BPC-157 appears.
07 — Questions for your physician
Six questions worth printing.
- 01What is your primary board certification, and in what year did you obtain it?
- 02Is this peptide approved for what you are prescribing it for — and if not, what is the legal basis on which you are supplying it?
- 03Which human trials support this use, and what were their size and duration?
- 04Where does the product come from, and can you show me a certificate of analysis for this batch?
- 05What outcome will we measure, when, and what happens if it does not improve?
- 06What is the total cost for the first three months, in writing?
Providers offering peptide therapy
Listing in the registry is not an endorsement of any substance or protocol, and it is not a statement that a treatment is approved.
Reviewed September 2026 · Sources: FDA, EMA
This page reports on the state of research and regulation for orientation. It is not medical advice, not a recommendation for or against any substance, and not an offer. Regulatory status changes; the date shown is the date of our last verification. Discuss any treatment with a licensed physician.